Clinical trial
Psoriatic Immune Response to Tildrakizumab
NCT05390515 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Psoriatic Immune Response to Tildrakizumab
- Lead sponsor
- University of California, San Francisco
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- September 1, 2022
- Completion date
- September 1, 2028
- Enrollment
- 10 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
psoriasis vulgaris